Wex raises $34.5-million in rights offering

Wex Pharmaceuticals’ (TSX:WXI) rights offering has been fully subscribed, raising $34.5 million through the issuance of 265,483,177 restricted voting shares at a price of 13 cents a share. The company intends to use the proceeds to continue its research and development of tetrodotoxin and for general administrative costs and working capital. Controlling shareholder Pharmagesic (Holdings), [...]

Wex plans $34.5-million rights offering

Wex Pharmaceuticals (TSX:WXI) has filed for a rights offering to raise about $34.5-million, with proceeds earmarked to fund research and development, and for working capital. Under the plan, holders of restricted voting shares of Wex on Dec. 23 will receive rights to purchase 1.5 new shares at a subscription price of 13 cents.  The rights [...]

CK Life Sciences ups stake in Wex

A Hong Kong life sciences company has raised its stake in Wex Pharmaceuticals (TSX:WXI) of Vancouver to a total of 75.25% of the restricted voting shares outstanding by converting a $15-million convertible debenture of Wex at a price of 14.09 cents a share. CK Life Sciences International (Holdings) also received about 6.2 million shares of Wex [...]